Strategies for management of axillary lymph nodes in breast cancer;Les stratégies de prise en charge des ganglions axillaires dans les cancers du sein

Annales de Pathologie

Volumn 23, Issue 6, 2003, Pages 518-533

  De Mascarel, Isabelle ^a   MacGrogan, Gaëtan ^a  

^a INSTITUT BERGONIÉ   (France)

Author keywords

Breast axillary node metastases; Breast cancer; Immunohistochemistry; Sentinel lymph node

Indexed keywords

AXILLARY LYMPH NODE; BREAST CANCER; CANCER INFILTRATION; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; PATHOLOGIST; REVIEW; SENTINEL LYMPH NODE BIOPSY; TUMOR CELL;

ACADEMIES AND INSTITUTES; AXILLA; BREAST NEOPLASMS; CARCINOMA; CASE MANAGEMENT; FEMALE; FRANCE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MICROTOMY; NEOPLASM STAGING; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 1842471330     PISSN: 02426498     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. TNM/UICC 2003. Revision of the American Joint Committee on Cancer staging system for Breast Cancer. J Clin Oncol 2002; 20: 3628-36.
2. Masuda N, Tamaki Y, Sakita I, Ooka M, Ohnihi T, Kadota M et al. Clinical significance of micrometastases in axillary lymph nodes assessed by reverse transcription-polymerase chain reaction in breast cancer patients. Clin Cancer Res 2000; 6: 4176-85.
3. Wascher RA, Bostick PJ, Huynh KT, Turner R, Qi K, Giuliano AE et al. Detection of MAGE-A3 in breast cancer patients' sentinel lymph nodes. Br J Cancer 2001; 2: 1340-6.
4. Braun S, Cevatli BS, Assemi C, Janni W, Kentenich CR, Schindlebeck et al. Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy. J Clin Oncol 2001; 19: 1468-75.
5. Nemoto T, Vana J, Bedwani RN, Baker HW, Mc Gregor FH, Murphy GP. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer 1980; 45: 2917-24.
6. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status and survival in 24,740 breast cancer cases. Cancer 1989; 63: 181-7.
7. Newman LA, Kuever HM, Fornage B et al. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Am J Surg 2001; 181: 313-18.
8. Klauber-DeMore N, Bevilacqua JLB, van Zee KJ, Borgen P, Cody HS. Comprehensive review of the management of internal mammary lymph node metastases in breast cancer. J Am Coll Surg 2001; 193: 547-55.
9. Brito RA, Valero VV, Buzdar AU, Booser DJ, Ames F, Strom E et al. Long-term results of combined-modality therapy for locally advanced breast cancer with lateral supraclavicular metastases: the university of Texas MD Anderson Cancer Center Experience. J Clin Oncol 2001; 19: 628-33.
10. Weaver DL. Sentinel lymph nodes and breast carcinoma: which micrometastases are clinically significant? Proceedings of the annual meeting of the United States and Canadian Academy of Pathology. February 23, March 1, 2002.
11. Freneaux P, Nos C, Vincent-Salomon A, Genin P, Sigal-Zafrani B, Al Ghuzlan A et al. Histological detection of minimal metastatic involvement in axillary sentinel nodes: a rational basis for a sensitive methodology usable in daily practice. Mod Pathol 2002; 15: 641-6.
12. Turner RR, Giuliano AE, Hoon DS, Glass EC, Krasne DL. Pathologic examination of sentinel lymph node for breast carcinoma. World J Surg 2001; 25: 798-805.
13. Turner RR. Histopathologic assessment of the sentinel lymph node in breast cancer. Ann Surg Oncol 2001; 8: 56s-59s.
14. Friedman S, Bertin F, Mouriesse H, Benchabat A, Henin J, Sarrazin D et al. Importance of tumor cells in axillary node sinus margins («clandestine» metastases) discovered by serial sectioning in operable breast carcinoma. Acta Oncol 1988; 27: 483-7.
15. Huvos AG, Hutter RVP, Berg JW. Significance of axillary macrometastases and micrometastases in mammary cancer. Ann Surg 1971; 173: 44-6.
16. Pickren JW. Significance of occult metastases. A study of breast cancer. Cancer 1961; 14: 1266-71.
17. Fisher ER, Swamidoss S, Lee CH, Rockette H, Redmond C, Fisher B. Detection and significance of occult axillary node metastases in patients with invasive breast cancer. Cancer 1978; 42: 2025-31.
18. Rosen PP, Saigo PE, Braun DW, Weathers E, de Palo A. Predictors of recurrence in stade I (T1 N0 M0) breast carcinoma. Ann Surg 1981; 193: 15-25.
19. Rosen PP, Saigo PE, Braun DW, Weathers E, Fracchia AA, Kinne DW. Axillary micro- and macrometastases in breast cancer. Ann Surg 1981; 194: 585-91.
20. Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S. Pathological prognostic factors in stage I (T1 N0 M0) and stage II (T1 N1 M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol 1989; 7: 1239-51.
21. Fisher E, Palekar A, Rockette H, Redmond C, Fisher B. pathologic findings from the national surgical adjuvant breast project (protocol n° 4): V. significance of axillary nodal micro- and macrometastases. Cancer 1978; 42: 2032-8.
22. Trojani M, de Mascarel, I, Bonichon F, Coindre JM, Delsol G. Micrometastases to axillary lymph nodes from carcinoma of breast: detection by immuno-histochemistry and prognostic significance. Br J Cancer 1987; 55: 303-6.
23. Trojani M, de Mascarel I, Coindre JM, Bonichon F. Micrometastases to axillary lymph nodes from invasive lobular carcinoma of breast: detection by immuno-histochemistry. Br J Cancer 1987; 56: 838-9.
24. Byrne J, Waldron R, McAvinchey D, Dervan P. The use of monoclonal antibodies for the histopathological detection of mammary axillary micrometastases. Eur J Surg Oncol 1987; 13: 409-11.
25. Sedmak DD, Meineke TA, Knechtges DS, Anderson J. Prognostic significance of cytokeratin-positive breast cancer metastases. Mod Pathol 1989; 2: 516-20.
26. Galea MH, Athanassiou E, Bell J, Dilks B, Robertson JF, Elston CW et al. Occult regional lymph node metastases from breast carcinoma: immunohistological detection with antibodies CAM 5.2 and NCRC-II. J Pathol 1991; 165: 221-7.
27. Chen ZL, Wen DR, Coulson WF, Giuliano AE, Cochran AJ. Occult metastases in the axillary lymph nodes of patients with breast cancer node negative by clinical and histologic examination and conventional histology. Dis Markers 1991; 9: 239-48.
28. Noel P, Chauvin F, Michot JP, Catimel G, Hesch M, Groleas, M. Valeur pronostique des micrométastases ganglionnaires détectées par analyse immunohistochimique. Ann Pathol 1991; 11: 309-15.
29. Byrne J, Horgan PG, England S, Callaghan J, Given HF. A preliminary report on the usefulness of monoclonal antibodies to CA 15-3 and MCA in the detection of micrometastases in axillary lymph nodes draining primary breast carcinoma. Eur J Cancer 1992; 28: 658-60.
30. de Mascarel I, Bonichon F, Coindre JM, Trojani M. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up. Br J Cancer 1992; 66: 523-7.
31. Hainsworth PJ, Tjandra JJ, Stillwell RG, Machet D, Henderson MA, Rennie GC et al. Detection and significance of occult metastases in node-negative breast cancer. Br J Surg 1993; 80: 459-63.
32. Elson CE, Kufe D, Johnston WW. Immunohistochemical detection and significance of axillary lymph node micrometastases in breast carcinoma. A study of 97 cases. Anal Quant Cytol Histol 1993; 15: 171-8.
33. Nasser IA, Lee AK, Bosari S, Saganich R, Heatley G, Silverman ML. Occult axillary lymph node metastases in «node-negative» breast carcinoma. Hum Pathol 1993; 24: 950-7.
34. McGuckin MA, Cummings MC, Walsh MD, Hohn BG, Bennett IC, Wright RG. Occult axillary node metastases in breast cancer: their detection and prognostic significance. Br J Cancer 1996; 73: 88-95.
35. Cote RJ, Peterson HF, Chaiwun B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M et al. Role of immunohistochemical detection of (DFP) lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet 1999; 354: 896-900.
36. Millis RR, Springall R, Lee AHS, Ryder K, Rytina ERC, Fentiman IS. Occult axillary lymph node metastases are of no prognostic significance in breast cancer. Br J Cancer 2002; 86: 396-40
37. de Mascarel I, Mac Grogan G, Picot V, Mathoulin-Pelissier S. Prognostic significance of immunohistochemically detected breast cancer node metastases in 218 patients. Br J Cancer 2002; 87: 70-4.
38. Dowlatshahi K, Fan M, Snider HC, Habib FA. Lymph node mircometastases from breast carcinoma: reviewing the dilemma. Cancer 1997; 80: 1188-97.
39. de Mascarel I, Trojani M, Abadjian G, Durand M, Bonichon F, Coindre JM et al. Ganglions axillaires dans les cancers du sein. Comparaison des techniques d'analyse histologique standard et en coupes macroscopiquement sériées. Bull Cancer 1982; 69: 451-5.
40. Schwartz GF, Giuliano AE, Veronesi U. Proceeding of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast. The consensus conference committee. April 19-22, 2001. Philadelphia, Pennsylvania. Cancer 2002; 94: 2542-51.
41. Rutqvist LA, Pettersson D, Johansson H. Adjuvant radiation therapy versus surgery alone in operable breast cancer: long-term follow-up of a randomized clinical trial. Radiother Oncol 1993; 26: 104-10.
42. Freneaux P. Ganglion sentinelle, histopathologie. In: Ganglion sentinelle & cancer du sein. Techniques et indications. Paris: 7 décembre 2001.
43. Viale G, Maiorano E, Mazzarol G, Zurrida S, Galimberti V, Luini A et al. Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer 2001; 92: 1378-84.
44. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N England J Med 2003; 349: 546-53.
45. Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997; 15: 2345-50.
46. Offodile R, Hoh C, Barsky SH, Nelson SD, Elashoff R, Eilber FR et al. Minimally invasive breast carcinoma staging using lymphatic mapping with radiolabeled dextran. Cancer 1998; 82: 1704-8.
47. Turner RR, Chu KU, Oi K, Botnick LE, Hansen NM, Glass EC, Giuliano AE. Pathologic features associated with non sentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer 2000; 89: 574-81.
48. Dowlatshahi K, Fan M, Anderson JM, Bloom KJ. Occult metastases in sentinel nodes of 200 patients with operable breast cancer. Ann Surg Oncol 2001; 8: 675-82.
49. Torrenga H, Rahusen FD, Maijer S, Borgstein PJ, van Diest PJ. Sentinel node investigation in breast cancer: detailed analysis of the yiels drom step sectioning and immunohistochemistry. J Clin Pathol 2001; 54: 550-2.
50. Fisher B, Wolmark N, Bauer M, Redmond C, Gebhardt M. The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. Surg Gynecol Obstet 1981; 152: 765-72.
51. Fisher B, Redmond C, Fisher ER, Bauer M, Wolmark N, Wickerham L et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985; 312: 674-81.
52. Harris JR, Osteen RT. Patients with early breast cancer benefit from effective axillary treatment. Breast Cancer Res 1985; 5: 17-21.
53. Graversen HP, Blichert-Toft M, Andersen JA, Zedeler K. Breast cancer: risk of axillary recurrence in node-negative patients following partial dissection of the axilla. Eur J Surg Oncol 1988; 14: 407-12.
54. Cantin J, Scarth H, Levine M, Hugi M. For the Steering Committee on Clinical Practice. Guidelines for the care and treatment of breast cancer. CMAJ 2001; 165: 166-73.
55. Ball ABS, Fish S, Waters R, Thomas JM. Radical axillary dissection in the staging and treatment of breast cancer. Ann R Coll Surg Engl 1992; 74: 126-9.
56. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997; 337: 949-55.
57. Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999; 353: 1641-8.
58. Miltenburg DM, Miller C, Karamlou TB, Brunicardi FC. Meta-analysis of sentinel lymph node biopsy in breast cancer. J Surg Res 1999; 84: 138-42.
59. Simmons RM. Review of lymph node credentialing: how many cases are enough? J Am Coll Surg 2001; 193: 206-9.
60. Krishnamurthy S, Sahin A, Middleton LP, Symmans FW, Gilcrease MG, Sneige N, Singletary ES et al. Intraoperative imprint cytology for evaluation of axillary sentinel lymph nodes in breast cancer. Mod Pathol 2003; 16: 37A.
61. Turner RR, Ollila DW, Stern S, Giuliano AE. Optimal histopathologic examination of the sentinel lymph node for breast carcinoma staging. Am J Surg Pathol 1999; 23: 263-7.
62. Colpaert C, Vermeulen P, Jeuris W, van Beest P, Goovaert G, Weyler J et al. Early distant relapse in "node-negative" breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumor. J Pathol 2001; 193: 442-9.
63. Mathieu MC, Suciu V, Garbay JR, Lumbroso J, Travagli JP. Isolated tumor cells in the sentinel node and risk of axillary non sentinel node involvement in patients with breast carcninomas. Abstract 169. Congress of USCAP. Washington, March 2003.
64. Weaver DL, Krag DN, Ashikaga T, Harlow SP, O'Connell M et al. Pathologic analysis of sentinel and non sentinel lymph nodes in breast carcinoma. A multicentric study. Cancer 2000; 88: 1099-107.
65. Mathiesen O, Carl J, Bonderup O, Panduro J. Axillary sampling and the risk of erroneous staging of breast cancer. An analysis of 960 consecutive patients. Acta Oncol 1990; 29: 721-5.
66. Axelsson CK, Mouridsen HT, Zedeler K. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. Eur J Cancer 1992; 28: 1415-8.
67. Kutiyanawala MA, Sayed M, Stotter A, Windle R, Rew D. Staging the axilla in breast cancer: an audit of lymph-node retrieval in one UK regional centre. Eur J Surg Oncol 1998; 24: 280-2.
68. e édition, mise à jour). Paris: Éditions John Libbey Eurotext, 2001.
69. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM. Prognostic factors in breast cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 966-78.
70. Association of directors of Anatomic and Surgical Pathology. ADAPS Recommendations for Processing and Reporting Lymph node Specimens Submitted for Evaluation of Metastatic Disease. The American Journal of Surgical Pathology 2001; 25: 961-63.
71. European Working Group for Breast Screening Pathology: Cserni G, Amendoeira I, Apostolokas N, Bellocq JP, Bianchi S, Bussolati G et al. Pathological Work-up of sentinel lymph nodes in breast cancer. Review of current data to be considered for the formulation of guidelines. European Journal of Cancer 2003; 39: 1654-67.
72. de Mascarel I, Mac Grogan G, Mathoulin-Pélissier S, Soubeyran I, Picot V, Coindre JM. Breast ductal carcinoma in situ with microinvasion. A definition supported by a long term study of 1248 serially sectioned ductal carcinomas. Cancer 2002; 94: 2134-42.
73. Weaver DL. Sentinel lymph node biopsy in breast cancer: creating controversy and defining new standards. Adv Anat Pathol 2001; 8: 65-73.